Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
This policy change follows extensive review of clinical evidence and could influence health authorities worldwide, including Health Canada's regulatory approach to these medications
This group will be facilitated through a fat-affirming, weight stigma lens that prioritizes the demonstrated history of risk and harm associated with intentional weight-loss, including GLP-1s
& Shahid, R
P-LLY Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about retatrutide as a potential treatment for adults with obesity or overweight and at least one weight-related comorbidity, potential efficacy and tolerability of retatrutide, and the timeline for future readouts, presentations, and other milestones relating to retatrutide and its clinical trials and reflects Lilly's current beliefs and expectations
US$ 28.38
US$ 21.75
US$ 25.81
US$ 19.98
